Format

Send to

Choose Destination
JAMA. 1982 Jan 22-29;247(4):475-7.

Protection against endometrial carcinoma by combination-product oral contraceptives.

Abstract

Seventy-nine patients with endometrial carcinoma were compared with 203 control subjects regarding their use of combination-product oral contraceptives (OCs). Overall, 6.3% of patients and 15.3% of control subjects had used these products. The risk of endometrial cancer for users of OCs was less than half the risk for nonusers. Five years or more of use reduced the risk to a third. Recent users were strongly protected, whereas discontinuation resulted in risks returning to those of nonusers. Furthermore, OCs with predominantly progestational effects of intermediate formulations produced greater protection than those with predominantly estrogens. This pattern of results is biologically consistent with a protective effect of combination-product OCs against endometrial carcinoma.

PIP:

79 patients with endometrial carcinoma were compared with 203 control subjects regarding their use of combined oral contraceptives (OCs). The patients comprised all North Carolina residents with histologically confirmed endometrial carcinoma initially treated at North Carolina Memorial Hospital between 1970-76. Overall, 6.3% of patients and 15.3% of control subjects had used these products. The risk of endometrail cancer for users of OCs was less than half the risk for nonusers. 5 years or more of use reduced the risk to a third. Recent users were strongly protected, whereas discontinuation resulted in risks returning to those of nonusers. Furthermore, OCs with predominantly progestational effects or intermediate formulations produced greater protection than those predominantly estrogenic. This pattern is biologically consistent with a protective effect of combined OCs against endometrial carcinoma.

PMID:
7033575
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center